RHB Indonesia - Mandiri and Tabungan Negara Posted Improving Loan Growth (Bank Mandiri, Bank Tabungan Negara) Unknown Kamis, 06 April 2017




Good morning,
Mandiri and Tabungan Negara Posted Improving Loan Growth
 
Bank Mandiri (BMRI IJ, Neutral, TP: IDR11,600) and Bank Tabungan Negara (BBTN IJ, BUY, TP: IDR2,600) posted improving loan growth in 1Q17. BBTN posted close to 20% YoY loan growth, supported by subsidized mortgage loan. The company keeps loan growth target at 21-23% in FY17 with NIM at around 4.5-5%. Meanwhile, Bank Mandiri posted a 13% YoY loan growth supported by corporate and consumer credit. Corporate loan is enhanced by palm oil, consumer goods, and automotive industry. Consumer loan is supported by mortgage loan, multipurpose loan, and vehicle loans.

Such loan growth figures were in line with our expectation. For Mandiri, asset quality would remain our main concern as we expect gross NPL ratio would reach 3.7% by end of year (end-2016: 4%). We maintain our top pick on BTN due to its strong focus on subsidised mortgage segment and improvement in asset quality to 2.5% based on our forecast (end-2016: 2.8%). We assume 21% YoY growth in subsidised mortgages while total loan book would grow by 17.1% this year. (Eka Savitri)

Link to Daily report: Indonesia Morning Cuppa 060417





Media Highlights:

Corporate

MAP Boga Adiperkasa to undertake IPO
MAP Boga Adiperkasa (MBA), a subsidiary of Mitra Adiperkasa (MAPI IJ, BUY, TP: IDR6,675) will offer 20% of its shares to the public. MBA operates in the food and beverage industry, holding rights to five brands which are Starbucks, Pizza Express, Krispy Kreme, Cold Stone Creamery, and GODIVA. In mid-2016, MAPI issued IDR1.08trn in zero coupon bonds that could be converted to 29.9% of shares in MBA. (Kontan)

Comment: MAP Boga IPO spin-off will likely go at higher EV/Ebitda, but lower PE than the parent. This is MAPI's crown jewel, the cafe & restaurant segment's EBIT and PBT grew 46% & 86% in 2016A. General Atlantic PE bought 30% stakes at MAP Boga in end of 2016 at valuation of ~13x EV/Ebitda & ~28x PE 2016A. Peers, SBUX US & BFD MK trades at 11-15x EV/Ebitda and 27-28x PE 2017F. (Stifanus Sulistyo)

Surya Semesta shareholders approve Cipali divestment
Erajaya looks to sell IoT products
Indofarma looks to achieve IDR15bn in profits
Nusa Raya Cipta aims IDR3.3trn in new contract this year
Sariguna targets IDR57bn from IPO
Merdeka Cooper Gold starts production of Tujuh Bukit mine


Our Recent Publication:
Indonesia Strategy: Exuberance Over Positives Ahead
Sector Update: Coal Mining - Monetising Australian Coal Supply Disruption
Economics Update: Harvest Season Brings Some Relief In March Food Prices
Results Review: Harum Energy – FY17 Earnings To Spike
Sector Update: Regional Plantation – Time To Lock In Profits
Company Update: Astra Agro Lestari – Downtrend In CPO Prices Push Share Prices Down
Company Update: PP London Sumatra Indonesia – Downtrend In CPO Prices Push Share Prices Down
Results Review: Summarecon Agung – Weak Performance May Persist
Indonesia Economic Outlook: Stronger Growth As Exports & Government Spending Recover
Company Update: Tower Bersama Infrastructure – Moderated Growth And Stretched Balance Sheet


Best regards,

Helmy Kristanto
Director
Head of Indonesia Research
PT. RHB Securities Indonesia


Disclaimer: This message is intended only for the use of the individual or entity to whom it is addressed and may contain information that is confidential and privileged.  If you, the reader of this message, are not the intended recipient, you should not disseminate, distribute or copy this communication.  If you have received this communication by mistake, please notify us immediately by return email and delete the original message.  This message is transmitted on the condition that the recipient accepts the inherent risks in electronic data transmission and agrees to release RHB group and RHB Securities from any claim which the recipient may have as a result of any unauthorized duplication, reading or interference with the contents herein. The contents herein are made in the personal capacity of the above-named author and nothing herein shall be construed as professional advice or opinion rendered by RHB group and RHB Securities or on its behalf.